NewLink Genetics Co. (NLNK) Given Consensus Rating of “Hold” by Brokerages

Shares of NewLink Genetics Co. (NASDAQ:NLNK) have earned a consensus rating of “Hold” from the nine brokerages that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $6.10.

Several equities analysts have recently issued reports on NLNK shares. Cantor Fitzgerald set a $26.00 price target on shares of NewLink Genetics and gave the company a “buy” rating in a report on Friday, April 6th. Robert W. Baird lowered shares of NewLink Genetics from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $22.00 to $5.00 in a report on Monday, April 9th. Jefferies Group lowered shares of NewLink Genetics from a “buy” rating to a “hold” rating in a report on Friday, April 6th. Bank of America lowered shares of NewLink Genetics from a “buy” rating to a “neutral” rating in a research note on Friday, April 6th. Finally, ValuEngine lowered shares of NewLink Genetics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, May 8th.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Millennium Management LLC boosted its stake in NewLink Genetics by 56.6% in the 4th quarter. Millennium Management LLC now owns 2,347,359 shares of the biotechnology company’s stock worth $19,037,000 after purchasing an additional 848,752 shares during the period. BlackRock Inc. boosted its stake in NewLink Genetics by 21.3% in the 4th quarter. BlackRock Inc. now owns 2,311,834 shares of the biotechnology company’s stock worth $18,750,000 after purchasing an additional 405,820 shares during the period. Redmile Group LLC boosted its stake in NewLink Genetics by 67.9% in the 4th quarter. Redmile Group LLC now owns 2,096,490 shares of the biotechnology company’s stock worth $17,003,000 after purchasing an additional 847,790 shares during the period. JPMorgan Chase & Co. boosted its stake in NewLink Genetics by 6,778.1% in the 1st quarter. JPMorgan Chase & Co. now owns 493,367 shares of the biotechnology company’s stock worth $3,577,000 after purchasing an additional 486,194 shares during the period. Finally, Wells Fargo & Company MN lifted its position in NewLink Genetics by 10.8% during the 1st quarter. Wells Fargo & Company MN now owns 413,905 shares of the biotechnology company’s stock worth $3,001,000 after buying an additional 40,223 shares in the last quarter. 53.04% of the stock is owned by hedge funds and other institutional investors.

Shares of NewLink Genetics traded up $0.08, hitting $5.15, on Monday, Marketbeat.com reports. 227,565 shares of the company’s stock traded hands, compared to its average volume of 1,048,280. NewLink Genetics has a one year low of $3.75 and a one year high of $19.30. The stock has a market capitalization of $188.43 million, a price-to-earnings ratio of -2.24 and a beta of 1.25.

NewLink Genetics (NASDAQ:NLNK) last announced its quarterly earnings results on Thursday, May 3rd. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.06. NewLink Genetics had a negative net margin of 193.44% and a negative return on equity of 55.64%. The company had revenue of $9.90 million during the quarter, compared to analyst estimates of $5.78 million. research analysts forecast that NewLink Genetics will post -2.17 earnings per share for the current fiscal year.

NewLink Genetics Company Profile

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing NLG2103, a combination of indoximod and standard of care checkpoint inhibitors, which is in Phase II clinical trial for treating patients with advanced melanoma; and Indigo301, a combination of indoximod with a checkpoint inhibitor that is in Phase III clinical trial for treating patients with advanced unresectable or metastatic melanoma, as well as combination of indoximod with other cancer therapeutics for patients with melanoma, pancreatic cancer, pediatric brain tumors, and acute myeloid leukemia.

Analyst Recommendations for NewLink Genetics (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply